We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

44 hedge funds and large institutions have $25.7M invested in AVEO Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less funds holding

Funds holding: 48 → 44 (-4)

10% less capital invested

Capital invested by funds: $28.5M → $25.7M (-$2.81M)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

70% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 10

Holders
44
Holders Change
-4
Holders Change %
-8.33%
% of All Funds
1.17%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
6
Increased
3
Reduced
10
Closed
10
Calls
$57K
Puts
–
Net Calls
+$57K
Net Calls Change
+$47K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$179K
2
Citadel Advisors
Citadel Advisors
Florida
+$40.8K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$18K
4
Goldman Sachs
Goldman Sachs
New York
+$15.9K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$15.9K

Top Sellers

Rank Fund Capital Flow
1
NC
Nexthera Capital
New York
-$498K
2
DCM
DAFNA Capital Management
California
-$249K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$92K
4
SIM
Spark Investment Management
New York
-$56.6K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$47K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$9.22M – – –
PA
2
Perceptive Advisors
New York
$2.77M – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$2.31M +$179K +19,000 +8%
NLVP
4
New Leaf Venture Partners
New York
$2.31M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.15M -$47K -4,990 -2%
SCM
6
Sarissa Capital Management
Connecticut
$1.78M – – –
BIT
7
BlackRock Institutional Trust
California
$1.73M – – –
CAM
8
Cormorant Asset Management
Massachusetts
$968K – – –
DVC
9
Deer VI & Co
New York
$601K – – –
BCM
10
Bridgeway Capital Management
Texas
$458K – – –
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$272K +$15.9K +1,690 +6%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$269K – – –
SIM
13
Spark Investment Management
New York
$207K -$56.6K -6,014 -21%
CC
14
Cannell & Co
New York
$113K – – –
Northern Trust
15
Northern Trust
Illinois
$91K – – –
Tudor Investment Corp
16
Tudor Investment Corp
Connecticut
$75K – – –
Bank of New York Mellon
17
Bank of New York Mellon
New York
$58K -$11.4K -1,207 -16%
TRCT
18
Tower Research Capital (TRC)
New York
$40K +$10.8K +1,150 +34%
Citadel Advisors
19
Citadel Advisors
Florida
$39K +$40.8K +4,329 New
EWM
20
Evercore Wealth Management
New York
$35K – – –
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$30K – – –
State Street
22
State Street
Massachusetts
$22K – – –
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
$17K +$18K +1,911 New
GC
24
Guggenheim Capital
Illinois
$16K -$132 -14 -0.8%
Connor, Clark & Lunn Investment Management (CC&L)
25
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$16K – – –
1
2

AVEO Hedge Fund Activity: Q3 2016 in Review

44 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2016, worth a combined $25.7M — down 9.9% from $28.5M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of AVEO and 6 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $179K. The largest seller was Nexthera Capital, exiting entirely with an estimated $498K sold.

  • 44 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2016, down from 48 in Q2 2016.
  • Funds reported $25.7M of AVEO Pharmaceuticals, Inc. stock for Q3 2016, down 9.9% quarter-over-quarter.
  • 6 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2016 and 10 closed out, a net change of -4 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2016 was Renaissance Technologies, an estimated $179K added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q3 2016 was Nexthera Capital, an estimated $498K sold.

Based on aggregated 13F filings for Q3 2016.